Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine

The Lancet Infectious Diseases

Volumn 12, Issue 5, 2012, Pages 408-414

  Grebely, Jason ^a   Prins, Maria ^c,d   Hellard, Margaret ^e   Cox, Andrea L ^f   Osburn, William O ^f   Lauer, Georg ^g   Page, Kimberly ^h   Lloyd, Andrew R ^b   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e BURNET INSTITUTE   (Australia)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VACCINE; VIRUS RNA;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; INTRAVENOUS DRUG ABUSE; NONHUMAN; PERSISTENT INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; REINFECTION; REVIEW; SEROCONVERSION; VIRAL CLEARANCE; VIREMIA;

HEPACIVIRUS; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL HEPATITIS VACCINES;

EID: 84860297348     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70010-5     Document Type: Review

References (84)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
2. Micallef JM, Kaldor JM, Dore GJ Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006, 13:34-41.
3. Bassett SE, Guerra B, Brasky K, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001, 33:1479-1487.
4. Major ME, Mihalik K, Puig M, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002, 76:6586-6595.
5. Nascimbeni M, Mizukoshi E, Bosmann M, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003, 77:4781-4793.
6. Lanford RE, Guerra B, Chavez D, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004, 78:1575-1581.
7. Prince AM, Brotman B, Lee DH, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 2005, 192:1701-1709.
8. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003, 197:1645-1655.
9. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80-88.
10. Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2009, 138:315-324.
11. Cox AL, Page K, Bruneau J, et al. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology 2009, 136:26-31.
12. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002, 359:1478-1483.
13. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW Hepatitis C virus reinfection in injection drug users. Hepatology 2006, 44:1139-1145.
14. Micallef JM, Macdonald V, Jauncey M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007, 14:413-418.
15. Aitken CK, Lewis J, Tracy SL, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008, 48:1746-1752.
16. Currie SL, Ryan JC, Tracy D, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008, 93:148-154.
17. van de Laar TJ, Molenkamp R, van den Berg C, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 2009, 51:667-674.
18. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult drug users: a prospective study of incident infection, resolution and reinfection. J Infect Dis 2009, 200:1216-1226.
19. Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2012, 55:1058-1069.
20. Halliday J, Klenerman P, Barnes E Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011, 10:659-672.
21. Busch MP Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001, 8:200-206.
22. Cox AL, Netski DM, Mosbruger T, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005, 40:951-958.
23. Page-Shafer K, Pappalardo BL, Tobler LH, et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 2008, 46:499-506.
24. Orland JR, Wright TL, Cooper S Acute hepatitis C. Hepatology 2001, 33:321-327.
25. Marcellin P Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999, 31(suppl 1):9-16.
26. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010, 138:123-135.
27. Grebely J, Matthews GV, Petoumenos K, Dore GJ Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. J Viral Hepat 2009, 17:896.
28. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009, 200:1216-1226.
29. Mosley JW, Operskalski EA, Tobler LH, et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008, 15:120-128.
30. Scott JD, McMahon BJ, Bruden D, et al. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clin Infect Dis 2006, 42:945-952.
31. Seeff LB The history of the " natural history" of hepatitis C (1968-2009). Liver Int 2009, 29(suppl 1):89-99.
32. Wang CC, Krantz E, Klarquist J, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007, 196:1474-1482.
33. Diepolder HM New insights into the immunopathogenesis of chronic hepatitis C. Antiviral Res 2009, 82:103-109.
34. Post J, Ratnarajah S, Lloyd AR Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009, 66:733-756.
35. Rehermann B Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1745-1754.
36. Blackard JT, Shata MT, Shire NJ, Sherman KE Acute hepatitis C virus infection: a chronic problem. Hepatology 2008, 47:321-331.
37. Lemon SM Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 2010, 285:22741-22747.
38. Bowen DG, Walker CM Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
39. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000, 6:578-582.
40. Rauch A, Gaudieri S, Thio C, Bochud PY Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009, 10:1819-1837.
41. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010, 139:1586-1592.
42. Grebely J, Petoumenos K, Hellard M, et al. Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010, 52:1216-1224.
43. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999, 73:2938-2946.
44. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
45. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?. J Viral Hepat 2007, 14:213-220.
46. Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007, 21:447-451.
47. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr 2003, 33:356-364.
48. Garten RJ, Lai SH, Zhang JB, Liu W, Chen J, Yu XF Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China. World J Gastroenterol 2008, 14:1878-1884.
49. Zhang M, Rosenberg PS, Brown DL, et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2006, 107:892-897.
50. Operskalski EA, Mack WJ, Strickler HD, et al. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol 2008, 41:255-263.
51. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
52. Melendez-Morales L, Konkle BA, Preiss L, et al. Chronic hepatitis B and other correlates of spontaneous clearance of hepatitis C virus among HIV-infected people with hemophilia. AIDS 2007, 21:1631-1636.
53. Piasecki BA, Lewis JD, Reddy KR, et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004, 40:892-899.
54. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008, 198:1337-1344.
55. Shores NJ, Maida I, Soriano V, Nunez M Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol 2008, 49:323-328.
56. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
57. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment tailure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345.
58. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-1898.
59. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002, 99:15669-15674.
60. Post JJ, Pan Y, Freeman AJ, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004, 189:1846-1855.
61. Zeremski M, Shu MA, Brown Q, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009, 16:10-20.
62. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009, 136:2377-2386.
63. Bartosch B, Bukh J, Meunier JC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 2003, 100:14199-14204.
64. Logvinoff C, Major ME, Oldach D, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004, 101:10149-10154.
65. Meunier JC, Engle RE, Faulk K, et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 2005, 102:4560-4565.
66. Lavillette D, Morice Y, Germanidis G, et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005, 79:6023-6034.
67. Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007, 104:6025-6030.
68. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G Immunity in hepatitis C infection. J Infect Dis 1992, 165:438-443.
69. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258:135-140.
70. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302:659-662.
71. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994, 343:388-390.
72. Aitken CK, Lewis J, Tracy SL, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008, 48:1746-1752.
73. Micallef JM, Macdonald V, Jauncey M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007, 14:413-418.
74. Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138:315-324.
75. Pham ST, Bull RA, Bennett JM, et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 2010, 52:1564-1572.
76. den Hollander JG, Rijnders BJ, van Doornum GJ, van der Ende ME Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. AIDS 2005, 19:639-640.
77. Dove L, Phung Y, Bzowej N, Kim M, Monto A, Wright TL Viral evolution of hepatitis C in injection drug users. J Viral Hepat 2005, 12:574-583.
78. Dore GJ, Micallef J Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity?. Hepatology 2007, 45:1330.
79. van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 2007, 22:183-193.
80. Grebely J, Thomas DL, Dore GJ HCV reinfection studies and the door to vaccine development. J Hepatol 2009, 51:628-631.
81. Lloyd AR, Jagger E, Post JJ, et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007, 85:24-32.
82. Neumann-Haefelin C, Spangenberg HC, Blum HE, Thimme R Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol 2007, 13:4839-4847.
83. Vickerman P, Grebely J, Dore GJ, et al. The more you look the more you find: effects of hepatitis C virus testing interval on re-infection incidence and clearance: implications for future vaccine study design. J Infect Dis 2012, published online Mar 29. 10.1093/infdis/jis213.
84. 3 Collaborative Group.